Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
The buyback offer would, if completed, be prior to the commencement of the separation and would be at a price of 21.5p per share
The group also said it “remains committed to ensure a secure financial position that can facilitate the commercialisation of the LIGHT system and crystallise the significant shareholder value associated with the provision of affordable proton therapy”
AstraZeneca said patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival.
The data, expected in the next month or so, will keep the biotech firm on track to take the first Affimer candidate into phase 1 studies, targeted for 2019
The Euronext-listed late clinical-stage company reported revenue of €517,738 for the three months to December 31, up from €58,556 in the third quarter.
The new once-daily medicine is to improve blood sugar level control in adults where single treatments of the drugs have proved inadequate.
The firm said the results showed patients given TroVax and low dose cyclophosphamide demonstrated “significant anti-5T4 immune responses”